PUXANO has developed a proprietary technology platform which fuses biotechnology, nanotechnology, and AI to revolutionize protein design and structure-based research to get access to those challenging targets where standard workflows fail. 

We hereby use a multi-layered approach that is specifically tailored to target proteins such as outer membrane proteins, glycoproteins, GPCRs, ion channels and fragile protein complexes. We have build a protein design toolbox for generating soluble analogues, multimer-stabilizing scaffolds, multi-epitope scaffolds, multimer-generating scaffolds or fiducials to build antigens for vaccine and antibody development, facilitate high-throughput drug screening or accelerate structure-guided drug development. 

Via our cryoEM grid portfolio, we can overcome all major problems in cryoEM sample preparation: low sample yields, complex dissassembly, preferred particle orientation. Furthermore, we are the first company that gained access to proteins isolated from native resources, enabling the study of patient-derived proteins beyond amyloids.  

Our research and platform technologies are trusted by top pharmaceutical and biotechnology companies and research centres worldwide. We can proudly state that we have accelerated drug discovery pipelines of targets that were blocked in the past and we thrive in making the impossible possible.